Biomarin Pharmaceutical Inc (NAS:BMRN)
$ 66.24 0.11 (0.17%) Market Cap: 12.62 Bil Enterprise Value: 12.27 Bil PE Ratio: 39.66 PB Ratio: 2.33 GF Score: 67/100

Biomarin Pharmaceutical Inc at Credit Suisse Healthcare Conference Transcript

Nov 08, 2022 / 04:35PM GMT
Release Date Price: $81.25 (-0.10%)
Tiago Felipe Fauth;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

All right. Perfect. Welcome, everyone, to the Credit Suisse Annual Healthcare Conference. I'm Tiago Fauth, I'm a lead biotech analyst at CS. We're joined today by BioMarin. We have Jeff, Chief Commercial Officer; and Brian, Chief Financial Officer for a fireside chat today. We'll try to leave about 5 minutes towards the end for Q&A if there are any questions from the audience.

Questions & Answers

Tiago Felipe Fauth;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

But I guess to kick it off, let's start big picture as BioMarin is kind of evolving towards larger indications in VOXZOGO ultra-rare. What does that mean in terms of the business strategy, operating leverage investments in the early stage pipeline, and we'll get into some more specifics following that.

Brian R. Mueller
BioMarin Pharmaceutical Inc. - Executive VP of Finance & CFO

Yes, great. Thanks so

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot